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Abstract Tetrathiomolybdate (TTM) avidly interacts with
copper and has recently been employed to reduce excess copper
in patients with Wilson disease. We found that TTM inhibits the
purified Enterococcus hirae CopB copper ATPase with an IC50
of 34 nM. Dithiomolybdate and trithiomolybdate, which
commonly contaminate TTM, inhibited the copper ATPases
with similar potency. Inhibition could be reversed by copper or
silver, suggesting inhibition by substrate binding. These findings
for the first time allowed an estimate of the high affinity of CopB
for copper and silver. TTM is a new tool for the study of copper
ATPases. ß 2001 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
Copper is essential and serves as cofactor for more than 30
enzymes, many of which are of key importance, such as super-
oxide dismutase to combat radical formation, cytochrome c
oxidase for cellular respiration, tyrosine oxidase in pigmenta-
tion, or lysyloxidase for connective tissue maturation [1]. Yet,
a surplus of copper is toxic and leads to radical formation and
oxidation of biomolecules. Therefore, copper homeostasis is a
key requisite for every organism.
The Gram-positive bacterium Enterococcus hirae has a well-
characterized copper homeostatic system. It is encoded by the
cop operon, which is composed of a promoter/operator region
followed by four genes that function in the control of cellular
copper: a repressor, a copper chaperone, and two copper
pumps [2^4]. The CopY repressor regulates the expression
of all four cop genes by binding to the promoter/operator in
a copper sensitive fashion [5] and the CopZ chaperone is in-
volved in intracellular copper routing [6]. The two copper
ATPases, CopA and CopB, belong to the CPx-type ATPases.
This class of heavy metal ATPases is highly conserved and
encountered from bacteria to humans [7]. CopA appears to
serve in the uptake of copper under copper limiting condi-
tions, and CopB in the extrusion of copper when it ap-
proaches toxic levels [8,9]. CopA and CopB share 35^40%
sequence identity with the human Menkes and Wilson copper
ATPases. Mutations in the genes encoding these ATPases can
result in severe copper dysbalance. In the case of Menkes
disease, this leads to a systemic copper de¢ciency. In Wilson,
toxic copper overload results in liver cirrhosis and neurolog-
ical symptoms. The human copper ATPases have so far not
been puri¢ed. To investigate the molecular basis of copper
transport and the e¡ect of disease mutations, we have previ-
ously employed puri¢ed CopB from E. hirae as a model sys-
tem [10].
Puri¢ed CopB is fully active without the addition of copper
to the system. This suggested that the a⁄nity of the enzyme
for copper is very high and that su⁄cient copper is contam-
inating the water and the reagents to fully activate CopB. We
tested a range of copper binding compounds in their ability to
scavenge residual copper and to inhibit CopB. Tetrathiomo-
lybdate (TTM) was thus found to be a potent inhibitor of
CopB. Thiomolybdates have the ability to complex copper
in mammals and to deplete their copper stores. This had ¢rst
been recognized in ruminants grazing in areas with molybde-
num-rich soil [11]. Molybdenum ingested by way of molybde-
num-rich grasses appears to be transformed, together with
sul¢des from dietary sulfur compounds, to thiomolybdates
by rumen bacteria [12]. The thiomolybdates subsequently
complex ingested as well as stored copper, leading to copper
de¢ciency. This observation has recently led to the use of
TTM in humans to combat copper overload in Wilson disease
[13]. TTM has also been reported to inhibit a variety of cu-
pro-enzymes in vitro, including ceruloplasmin, cytochrome c
oxidase, superoxide dismutase, and tyrosine oxidase [12].
We here show that di- tri-, and tetrathiomolybdate are po-
tent inhibitors of the CopB copper ATPase. The reversibility
of the inhibition by copper and silver ions points towards
metal chelation as the inhibitory mechanism and the low
IC50 of 34 nM suggests a very high a⁄nity (low Km) of
CopB for copper and silver. Thiomolybdates may thus be a
valuable new tool in the study of copper ATPases.
2. Materials and methods
2.1. Materials
ATP and ammonium tetrathiomolybdate were supplied by Sigma-
Aldrich (St. Louis, MO, USA). Dodecyl-L-D-maltoside was purchased
from Calbiochem-Novabiochem (San Diego, CA, USA). Growth me-
dia additives were supplied by Becton Dickinson (Franklin Lakes, NJ,
USA). Chemicals that were not speci¢ed are from Merck (Darmstadt,
Germany) or from Sigma-Aldrich, and were of analytical grade.
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2.2. Puri¢cation of thiomolybdates
Commercial TTM was separated by Sephadex column chromatog-
raphy into di-, tri- and tetrathiomolybdate, essentially as described by
Kelleher and Mason [14]. In brief, 2 ml of 0.15 M ammonium tetra-
thiomolybdate in 20 mM Tris^SO4, pH 7.5, was passed through a
2U15 cm Sephadex G-25 column (Amersham Pharmacia Biotech Eu-
rope, Freiburg, Germany). Fractions having the characteristic spectra
of di-, tri-, and tetrathiomolybdate were collected and stored frozen at
320‡C. They were used for experiments within 40 days of column
puri¢cation. Published extinction coe⁄cients were used to calculate
the concentrations [15].
2.3. Puri¢cation of CopB
Y1 cells overexpressing CopB [4] were grown in 16 l of N-media in
a fermenter to an OD546 of 0.5^0.7, induced with 0.1 mM of o-phen-
anthroline for 1 h and collected by centrifugation for 10 min at
8000Ug. The subsequent steps for the preparation of membranes
from E. hirae were carried out as previously described [16]. Batches
of 1 g of membrane protein were extracted with 1 g of dodecyl-L-D-
maltoside in 90 ml bu¡er G (20 mM Tris^SO4, pH 7.5, 5 mM MgSO4,
25 mM Na2SO4, 1 mM L-mercaptoethanol, 1 WM CuSO4, 20% (v/v)
glycerol), supplemented with 1/50 volume of a protease inhibitor cock-
tail [16] on ice for 90 min with constant stirring. The suspension was
centrifuged at 90 000Ug for 45 min and the supernatant loaded on a
2U11 cm Ni-NTA column (Qiagen AG, Basel, Switzerland), followed
by elution with a 32 ml linear 0^100 mM imidazole gradient in
G bu¡er without Na2SO4 and CuSO4, but containing 0.05% (w/v)
of dodecyl-L-D-maltoside. Purity was determined by sodium dodecyl
sulfate^polyacrylamide gel electrophoresis [17] followed by staining
with Coomassie blue. Enzyme assays were performed with CopB frac-
tions of greater than 90% purity. Protein concentrations were deter-
mined by the method of Bradford [18], using bovine serum albumin as
standard.
2.4. ATPase assays
Puri¢ed CopB (5 Wg) was preincubated in 200 Wl of assay bu¡er (20
mM Tris^SO4, 5 mM MgS04, 1 mM ascorbic acid, 0.05% dodecyl-L-
D-maltoside, pH 7.5) and thiomolybdates or other complexing agents
added as indicated for 5 min at 37‡C. The reactions were started by
the addition of 1 mM Na-ATP. After 10 min, 100 Wl of assay mix
were transferred to tubes containing 10 Wl of 0.5 M Na-EDTA to stop
the reaction. Released phosphate was subsequently determined with a
colorimetric assay [19]. Metal ion reversion assays were performed in
0.1 WM TTM as described above, except that increasing amounts of
CuSO4 or AgSO4 (0.3^100 WM) were included in the preincubation.
To test the reversibility of inhibition by dilution, 25 Wl of puri¢ed
CopB (150 Wg) containing 1 Wl of 2.5 WM di-, tri-, or tetrathiomolyb-
date were preincubated for 5 min at 37‡C, followed by a 100-fold
dilution into assay bu¡er. Activity measurements were started with
1 mM ATP and phosphate release assessed after 45 min as described
above.
3. Results and discussion
3.1. Inhibition of CopB by copper and silver
It is a fundamental concept of ATP driven ion pumps that
ATP hydrolysis and ion transport are coupled processes.
Thus, no ATP hydrolysis by CopB should be observable in
the absence of copper. Using puri¢ed CopB, a Vmax of 1.3
Wmol/min/mg and a Km for ATP of 0.5 mM had previously
been determined for ATP hydrolysis, but no stimulation by
copper could be observed [10]. To the contrary and as shown
here, copper and silver inhibited ATP hydrolysis (Fig. 1). The
lack of stimulation was ascribed to a very high a⁄nity of
CopB for copper in conjunction with signi¢cant contaminat-
ing copper in the assay system. By graphite-furnace atomic
absorption measurements we determined a mean concentra-
tion of 0.1 WM contaminating copper in the complete assay
system. At metal ion concentrations above 3 WM, substrate
inhibition ensued. While these metal ion concentrations can
only be taken as relative values due to the presence of di¡er-
ent complexing agents (L-mercaptoethanol, Tris, ATP), the
results suggested that the a⁄nity of CopB for metal ions is
very high.
3.2. Inhibition of CopB by copper scavengers
To deplete the assay system of copper, we employed the
common copper(I) complexing agents bicinchoninic acid
(BCA) and bathocuproindisulfonate (BCS). These chelators
inhibited CopB activity with similar potency (Fig. 2). The
observed IC50 values were 14 WM for BCA, and 4 WM for
BCS. Dithiothreitol (DTT) which forms copperthiolates sim-
ilarly exhibited an IC50 of 3 WM. These IC50 values are clearly
in excess of the contaminating copper level of 0.1 WM and
these copper scavengers were thus not able to compete e⁄-
ciently with CopB for copper.
TTM (MoS234 ) is a potent copper binding agent which is
known to remove copper from metallothionein in vivo [20]
and which inhibits several cuproenzymes in vitro [14,21^23].
However, TTM is usually contaminated by the oxidation
products trithiomolybdate (MoOS233 ) and dithiomolybdate
(MoO2S232 ), as well as by uncharacterized contaminants [14].
Using chromatographic means (see Section 2) we puri¢ed di-,
Fig. 1. Inhibition of CopB by copper and silver ions. Copper (a)
and silver (b) were added to the assay as indicated in the ¢gure.
The activity of CopB was measured as described in Section 2 and is
shown as the mean þ standard deviation of the relative activity of
three experiments.
Fig. 2. Inhibition of CopB by copper chelators. CopB was preincu-
bated with TTM (b), DTT (R), or BCA (F), followed by activity
measurements as described in Section 2. The relative activity of
CopB is shown as the mean þ standard deviation of three experi-
ments.
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tri- and tetrathiomolybdate, characterized by their typical col-
ors (yellow, orange and red, respectively) and their distinct
spectra. The contamination of the commercial ammonium
tetrathiomolybdate preparation that we used with di- and tri-
thiomolybdate was 0.3 and 1.6%, respectively. In addition, it
contained a brown, insoluble fraction that remained on the
top of the column.
Puri¢ed TTM inhibited CopB with an IC50 of 34 nM (Fig.
2). Di- and trithiomolybdate were as potent as TTM (not
shown). The stoichiometry of copper^TTM complexes has
previously been reported to be one [20]. Assuming that
TTM inhibits CopB by sequestering copper, an upper limit
of the Km of CopB for copper of 66 nM can be approximated
(100 nM contaminating copper334 nM TTM-bound cop-
per = 66 nM residual copper; assuming negligible dissociation
of copper from Cu^TTM). The true Km is most likely even
lower, since part of the contaminating copper will be tightly
bound to other components of the assay system. In yeast, it
has been estimated that there is less than one free copper ion
per cell [24]. It appears likely that a similar situation prevails
in bacteria. Since CopB secretes copper from the cell, it must
be endowed with a very high a⁄nity for copper and a Km for
copper of or below 66 nM appears apt. It should be noted
that due to the acid sensitivity of the molybdates, all measure-
ments were conducted at pH 7.5 rather than at the pH opti-
mum of CopB of pH 5.5 [10].
3.3. Kinetic analysis of thiomolybdate inhibition
Kinetic analysis of the inhibition by TTM exhibited mixed
uncompetitive/non-competitive kinetics (Fig. 3). This nature
of the inhibition clearly argues against an interaction of
TTM with the ATP binding site, which would result in inhi-
bition that is competitive with ATP. In all likelihood, TTM
inhibition arises from complexation of copper, either in solu-
tion or by formation of tertiary TTM^Cu^CopB complexes.
The formation of such complexes is suggested by the capabil-
ity of TTM to extract tightly bound copper from proteins and
has been demonstrated for metallothionein [20]. To fully
understand the mode of TTM inhibition would require a
more thorough kinetic analysis which is beyond the realm
of this work.
3.4. Reversion of thiomolybdate inhibition by dilution
The reversibility of the inhibition of CopB by thiomolyb-
dates was analyzed by dilution experiments. CopB was essen-
tially fully inhibited by 100 nM di-, tri-, or tetrathiomolyb-
date. This inhibition could be reversed on average to 50% by
lowering the inhibitor concentration to 1 nM by a 100-fold
dilution (Table 1). In comparison, thiomolybdates directly
added at 1 nM only caused an approximately 15% inhibition.
Thus, the inhibition of CopB by thiomolybdates is at least
partially reversible. Bovine and ovine ceruloplasmin oxidase
inhibited by TTM could be fully reactivated by removal of the
drug [14,22]. Full reversibility of the CopB inhibition by thio-
molybdates may be compromised by chemical interaction of
CopB with the inhibitors or by their partial oxidation and/or
aggregation in our in vitro assay system substrate between the
enzyme binding site of CopB and TTM. If the commercial
TTM preparation was used without puri¢cation, it inhibited
with similar potency, but the inhibition was largely irrevers-
ible, probably due to aggregation phenomena with the insolu-
ble fraction in the TTM preparation.
Fig. 3. E¡ect of ATP concentration on TTM inhibition. Linewea-
ver^Burk plot of the rate of ATP hydrolysis (v) by CopB at varying
ATP concentrations (S) and in the presence of 0 (b), 34 nM (F),
and 40 nM TTM (R). The copper concentration was 0.1 WM. Other
details were as described in Section 2.
Fig. 4. Reversion of TTM inhibition by copper and silver. CopB in
the presence of 0.1 WM TTM, resulting in s 95% inhibition, was in-
cubated with increasing concentration of copper (a) and silver (b).
The relative activity of CopB was measured as described in Section
2 and is shown as the mean þ standard deviation of three experi-
ments.
Table 1
Inhibition of CopB by thiomolybdates and reactivation by dilution
Inhibitor % ATPase activitya
100 nM added re-diluted to 1 nMb 1 nM added
Tetrathiomolybdate 6 5 41 þ 4 81 þ 12
Trithiomolybdate 6 5 52 þ 7 85 þ 6
Dithiomolybdate 6 5 43 þ 17 86 þ 7
aThe data are the mean þ standard deviation of three experiments, expressed relative to an untreated control.
bCopB was preincubated with 100 nM thiomolybdate, followed by 100-fold dilution with assay bu¡er.
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3.5. Reversion of thiomolybdate inhibition by copper and silver
If the inhibition of CopB by thiomolybdates is indeed due
to the complexation of copper required for enzyme turn-over,
it should be reversible by added copper or silver ions. As
shown in Fig. 4, increasing amounts of copper or silver ions
reversed the inhibition by TTM. Complete reversal of inhibi-
tion was observed with a three-fold molar excess of copper
and a 10-fold molar excess of silver ions over inhibitor. How-
ever, high copper and silver concentrations themselves inhib-
ited the ATPase, as shown in Fig. 1, accounting for the drop
in ATPase activity at high metal ion concentrations. It thus
appears that copper^thiomolybdate complexes are not inhib-
itory.
Taken together, TTM inhibition has allowed us to assign to
the CopB copper ATPase of E. hirae a maximal value of the
Km for copper of 66 nM. In addition, TTM represents a
novel, potent inhibitor of CopB and may be of wider use as
a new research tool in the investigation of copper ATPases.
Our ¢ndings are also of interest in the realm of TTM being
evaluated as a novel drug in the treatment of Wilson patients
with neurological symptoms [13]. If TTM is over-dosed and
thus not entirely complexed by copper, it could possibly in-
hibit any residual activity of mutant Wilson ATPase or the
Menkes copper ATPase, ATP7A, in Wilson patients and in-
troduce a therapeutic risk factor.
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